Data completeness
2/8 — Basic
Priority Review
LOPINAVIR AND RITONAVIR by Cipla is fixed-dose combination of hiv-1 antiviral drugs lopinavir [see microbiology ( )] and ritonavir. Approved for combination with other antiretroviral agents for the treatment of hiv-1 infection in adults, older).
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Lopinavir and ritonavir is a fixed-dose combination HIV-1 protease inhibitor used in combination with other antiretroviral agents for treatment of HIV-1 infection in adults and older patients. Ritonavir acts as a pharmacokinetic booster, inhibiting CYP3A-mediated metabolism to increase plasma levels of the active protease inhibitor lopinavir.
Pre-Launch
Pre-launch stage signals opportunity for commercial build-out, though team size and hiring velocity are uncertain pending market entry.
Mechanism of Action
fixed-dose combination of HIV-1 antiviral drugs lopinavir [see Microbiology ( )] and ritonavir. As co-formulated in KALETRA, ritonavir inhibits the CYP3A-mediated metabolism of lopinavir, thereby providing increased plasma levels of lopinavir.
Worked on LOPINAVIR AND RITONAVIR at Cipla? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.